Results 151 to 160 of about 33,357 (182)
Some of the next articles are maybe not open access.
Bupropion and Bupropion Analogs as Treatments for CNS Disorders
2014Bupropion, introduced as an antidepressant in the 1980s, is also effective as a smoking cessation aid and is beneficial in the treatment of methamphetamine addiction, cocaine dependence, addictive behaviors such as pathological gambling, and attention deficit hyperactivity disorder. (2S,3S)-hydroxybupropion is an active metabolite of bupropion produced
Hernán A. Navarro +5 more
openaire +3 more sources
Bupropion for weight reduction
Expert Review of Neurotherapeutics, 2007Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients.
Glen L. Xiong, Kishore M. Gadde
openaire +2 more sources
Journal of Toxicology: Clinical Toxicology, 1997
Bupropion is a unique monocyclic antidepressant that has been known to cause seizures in high therapeutic doses and in acute overdoses. Death due to ingestion, however, is a rare occurrence.We report a case of a 26-year-old man who ingested 23 g bupropion, developed seizures and hypoxia, and presented in cardiac arrest.
John F. Gualtieri +2 more
openaire +3 more sources
Bupropion is a unique monocyclic antidepressant that has been known to cause seizures in high therapeutic doses and in acute overdoses. Death due to ingestion, however, is a rare occurrence.We report a case of a 26-year-old man who ingested 23 g bupropion, developed seizures and hypoxia, and presented in cardiac arrest.
John F. Gualtieri +2 more
openaire +3 more sources
Drugs of Today, 2006
Bupropion was initially developed and licensed for the treatment of major depressive disorder in the United States in 1989. It was licensed as a pharmacotherapy for smoking cessation in the United States in 1997 and in the United Kingdom in 2000, and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder ...
openaire +3 more sources
Bupropion was initially developed and licensed for the treatment of major depressive disorder in the United States in 1989. It was licensed as a pharmacotherapy for smoking cessation in the United States in 1997 and in the United Kingdom in 2000, and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder ...
openaire +3 more sources
Eosinophilia Associated with Bupropion
Annals of Pharmacotherapy, 1995Objective: To describe the first incidence of eosinophilia following administration of bupropion. Case Summary: The patient was a 72-year-old woman admitted for evaluation of chest pain. During hospitalization, the eosinophil count reached 0.60 fraction of 1.00, with absolute eosinophil count of 6693 × 109/L and a white blood cell count of 18.5 × 109/L.
James A Mahowald +4 more
openaire +2 more sources
Journal of Clinical Psychopharmacology, 1990
The relationship between seizure occurrence and use of bupropion was examined on the basis of manufacturer's reports. The observed incidence of seizures with bupropion doses of 450 mg/day or less ranged from 0.35%-0.44%, depending on the method of calculation.
openaire +3 more sources
The relationship between seizure occurrence and use of bupropion was examined on the basis of manufacturer's reports. The observed incidence of seizures with bupropion doses of 450 mg/day or less ranged from 0.35%-0.44%, depending on the method of calculation.
openaire +3 more sources
Bupropion in the management of apathy
Journal of Psychopharmacology, 2004We report on three males with prominent apathy as part of the symptom complex of depression or organic brain disease. Significant clinical responses were observed following treatment with bupropion, an antidepressant with dopamine (DA) reuptake activity.
Corcoran, C, Wong, M L, O'Keane, V
openaire +4 more sources
Eosinophilia associated with bupropion
International Journal of Clinical Pharmacy, 2013A 48-year-old woman started treatment with bupropion 150 mg once daily for depressive symptoms. After 19 days she presented to her family physician complaining of myalgia and non-productive cough. The physical examination was normal and laboratory investigations showed an eosinophil count of 4.7 × 10(9)/L (0-0.5).
Borja Ruiz +4 more
openaire +3 more sources
Expert Opinion on Drug Safety, 2005
Cigarette smoking represents one of the most preventable causes of death worldwide. However, success rates for stopping smoking are disappointingly low and are associated with high relapse rates. There is a need for a successful form of smoking cessation therapy.
David Williams, Sarah Ross
openaire +3 more sources
Cigarette smoking represents one of the most preventable causes of death worldwide. However, success rates for stopping smoking are disappointingly low and are associated with high relapse rates. There is a need for a successful form of smoking cessation therapy.
David Williams, Sarah Ross
openaire +3 more sources
Bupropion in Parkinson's disease
Neurology, 1984Bupropion is an antidepressant, thought to be an indirect dopaminergic agonist. No significant sympathomimetic, anti-cholinergic, or MAO inhibitor effects have been reported. We evaluated this drug in 20 patients with idiopathic Parkinson's disease. Parkinsonism lessened by at least 30% (Northwestern University Disability Scale or Modified New York ...
Caroline M. Tanner +2 more
openaire +3 more sources